Selected research
Market Outlook & Growth Opportunities
Global Personalized Psychiatry Market Outlook and Growth Opportunities 2026
Market perspective
The global Personalized Psychiatry market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Personalized Psychiatry is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Personalized Psychiatry is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Personalized Psychiatry is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Personalized Psychiatry market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Personalized Psychiatry market include COMPASS Pathways, Mindstrong Health, Pear Therapeutics, Cogito, Kaia Health, Sooma, GenoMind, Empatica and Akili Interactive, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Personalized Psychiatry market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Personalized Psychiatry and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Personalized Psychiatry revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Personalized Psychiatry market.
Personalized Psychiatry Segment by Company
COMPASS Pathways
Mindstrong Health
Pear Therapeutics
Cogito
Kaia Health
Sooma
GenoMind
Empatica
Akili Interactive
Neuroverse
Personalized Psychiatry Segment by Type
Depression and Anxiety
Bipolar Disorder
Addiction
Other
Personalized Psychiatry Segment by Application
Mental Health Professionals
Patients
Healthcare Providers
Personalized Psychiatry Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Personalized Psychiatry status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Personalized Psychiatry key companies, revenue, market share, and recent developments.
3. To split the Personalized Psychiatry breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Personalized Psychiatry market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Personalized Psychiatry significant trends, drivers, influence factors in global and regions.
6. To analyze Personalized Psychiatry competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Personalized Psychiatry market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Personalized Psychiatry and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Personalized Psychiatry.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Personalized Psychiatry industry.
Chapter 3: Detailed analysis of Personalized Psychiatry company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Personalized Psychiatry in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Personalized Psychiatry in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Depression and Anxiety
- Bipolar Disorder
- Addiction
- Other
Applications
- Mental Health Professionals
- Patients
- Healthcare Providers
Companies covered
- COMPASS Pathways
- Mindstrong Health
- Pear Therapeutics
- Cogito
- Kaia Health
- Sooma
- GenoMind
- Empatica
- Akili Interactive
- Neuroverse
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Personalized Psychiatry Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Personalized Psychiatry Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Personalized Psychiatry Market Dynamics
- 2.1 Personalized Psychiatry Industry Trends
- 2.2 Personalized Psychiatry Industry Drivers
- 2.3 Personalized Psychiatry Industry Opportunities and Challenges
- 2.4 Personalized Psychiatry Industry Restraints
3 Personalized Psychiatry Market by Company
- 3.1 Global Personalized Psychiatry Company Revenue Ranking in 2025
- 3.2 Global Personalized Psychiatry Revenue by Company (2021-2026)
- 3.3 Global Personalized Psychiatry Company Ranking (2024-2026)
- 3.4 Global Personalized Psychiatry Company Manufacturing Base and Headquarters
- 3.5 Global Personalized Psychiatry Company Product Type and Application
- 3.6 Global Personalized Psychiatry Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Personalized Psychiatry Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Personalized Psychiatry Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Personalized Psychiatry Market by Type
- 4.1 Personalized Psychiatry Type Introduction
- 4.1.1 Depression and Anxiety
- 4.1.2 Bipolar Disorder
- 4.1.3 Addiction
- 4.1.4 Other
- 4.2 Global Personalized Psychiatry Sales Value by Type
- 4.2.1 Global Personalized Psychiatry Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Personalized Psychiatry Sales Value by Type (2021-2032)
- 4.2.3 Global Personalized Psychiatry Sales Value Share by Type (2021-2032)
5 Personalized Psychiatry Market by Application
- 5.1 Personalized Psychiatry Application Introduction
- 5.1.1 Mental Health Professionals
- 5.1.2 Patients
- 5.1.3 Healthcare Providers
- 5.2 Global Personalized Psychiatry Sales Value by Application
- 5.2.1 Global Personalized Psychiatry Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Personalized Psychiatry Sales Value by Application (2021-2032)
- 5.2.3 Global Personalized Psychiatry Sales Value Share by Application (2021-2032)
6 Personalized Psychiatry Regional Value Analysis
- 6.1 Global Personalized Psychiatry Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Personalized Psychiatry Sales Value by Region (2021-2032)
- 6.2.1 Global Personalized Psychiatry Sales Value by Region: 2021-2026
- 6.2.2 Global Personalized Psychiatry Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Personalized Psychiatry Sales Value (2021-2032)
- 6.3.2 North America Personalized Psychiatry Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Personalized Psychiatry Sales Value (2021-2032)
- 6.4.2 Europe Personalized Psychiatry Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Personalized Psychiatry Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Personalized Psychiatry Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Personalized Psychiatry Sales Value (2021-2032)
- 6.6.2 South America Personalized Psychiatry Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Personalized Psychiatry Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Personalized Psychiatry Sales Value Share by Country, 2025 VS 2032
7 Personalized Psychiatry Country-level Value Analysis
- 7.1 Global Personalized Psychiatry Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Personalized Psychiatry Sales Value by Country (2021-2032)
- 7.2.1 Global Personalized Psychiatry Sales Value by Country (2021-2026)
- 7.2.2 Global Personalized Psychiatry Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.7.2 France Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.14.2 China Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.17.2 India Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Personalized Psychiatry Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Personalized Psychiatry Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Personalized Psychiatry Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 COMPASS Pathways
- 8.1.1 COMPASS Pathways Company Information
- 8.1.2 COMPASS Pathways Business Overview
- 8.1.3 COMPASS Pathways Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 8.1.4 COMPASS Pathways Personalized Psychiatry Product Portfolio
- 8.1.5 COMPASS Pathways Recent Developments
- 8.2 Mindstrong Health
- 8.2.1 Mindstrong Health Company Information
- 8.2.2 Mindstrong Health Business Overview
- 8.2.3 Mindstrong Health Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 8.2.4 Mindstrong Health Personalized Psychiatry Product Portfolio
- 8.2.5 Mindstrong Health Recent Developments
- 8.3 Pear Therapeutics
- 8.3.1 Pear Therapeutics Company Information
- 8.3.2 Pear Therapeutics Business Overview
- 8.3.3 Pear Therapeutics Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 8.3.4 Pear Therapeutics Personalized Psychiatry Product Portfolio
- 8.3.5 Pear Therapeutics Recent Developments
- 8.4 Cogito
- 8.4.1 Cogito Company Information
- 8.4.2 Cogito Business Overview
- 8.4.3 Cogito Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 8.4.4 Cogito Personalized Psychiatry Product Portfolio
- 8.4.5 Cogito Recent Developments
- 8.5 Kaia Health
- 8.5.1 Kaia Health Company Information
- 8.5.2 Kaia Health Business Overview
- 8.5.3 Kaia Health Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 8.5.4 Kaia Health Personalized Psychiatry Product Portfolio
- 8.5.5 Kaia Health Recent Developments
- 8.6 Sooma
- 8.6.1 Sooma Company Information
- 8.6.2 Sooma Business Overview
- 8.6.3 Sooma Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 8.6.4 Sooma Personalized Psychiatry Product Portfolio
- 8.6.5 Sooma Recent Developments
- 8.7 GenoMind
- 8.7.1 GenoMind Company Information
- 8.7.2 GenoMind Business Overview
- 8.7.3 GenoMind Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 8.7.4 GenoMind Personalized Psychiatry Product Portfolio
- 8.7.5 GenoMind Recent Developments
- 8.8 Empatica
- 8.8.1 Empatica Company Information
- 8.8.2 Empatica Business Overview
- 8.8.3 Empatica Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 8.8.4 Empatica Personalized Psychiatry Product Portfolio
- 8.8.5 Empatica Recent Developments
- 8.9 Akili Interactive
- 8.9.1 Akili Interactive Company Information
- 8.9.2 Akili Interactive Business Overview
- 8.9.3 Akili Interactive Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 8.9.4 Akili Interactive Personalized Psychiatry Product Portfolio
- 8.9.5 Akili Interactive Recent Developments
- 8.10 Neuroverse
- 8.10.1 Neuroverse Company Information
- 8.10.2 Neuroverse Business Overview
- 8.10.3 Neuroverse Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 8.10.4 Neuroverse Personalized Psychiatry Product Portfolio
- 8.10.5 Neuroverse Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst